Takeda's TAK-881 meets primary endpoint in Phase 2/3 PID trial

October 14, 2026 8:00 AM

Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced results from its pivotal Phase 2/3 IgGNITE clinical trial evaluating investigational TAK-881 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found